Pirodomast

Pirodomast

SCHEMBL607268

O=c1c(N2CCCC2)c(O)c2cccnc2n1-c1ccccc1.O=c1ccc2cccnc2[nH]1

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LOXL3 P58215 1/20 0.43
LOXL2 Q9Y4K0 1/20 0.43
ALDH1A1 P00352 4/20 0.41
KDM4E B2RXH2 2/20 0.41
FEN1 P39748 1/20 0.41
PDE4A P27815 7/20 0.41
PDE4B Q07343 6/20 0.41
PDE4C Q08493 6/20 0.41
PDE4D Q08499 6/20 0.41
TSHR P16473 2/20 0.38
CYP2C19 P33261 2/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
LMNA P02545 1/20 0.37
PDE1A P54750 1/20 0.37
PDE1B Q01064 1/20 0.37
GAA P10253 2/20 0.36
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pirodomast SCHEMBL29385413 0.87 FEN1 (0.52) LOXL3LOXL2ALDH1A1KDM4EFEN1
Pirodomast SCHEMBL125348 0.87 FEN1 (0.52) LOXL3LOXL2ALDH1A1KDM4EFEN1
SCHEMBL9629983 0.86 FEN1 (0.51) LOXL3LOXL2ALDH1A1KDM4EFEN1
Pirodomast SCHEMBL9488218 0.86 FEN1 (0.51) LOXL3LOXL2ALDH1A1KDM4EFEN1
Water SCHEMBL9629740 0.85 FEN1 (0.50) LOXL3LOXL2ALDH1A1KDM4EFEN1
SCHEMBL9629745 0.77 FEN1 (0.48) LOXL3LOXL2ALDH1A1KDM4EFEN1
Water SCHEMBL9629016 0.76 FEN1 (0.47) LOXL3LOXL2ALDH1A1KDM4EFEN1
Water SCHEMBL10427748 0.74 MAPT (0.44) ALDH1A1KDM4EFEN1PDE4BPDE4D
Water SCHEMBL10582943 0.74 FEN1 (0.46) ALDH1A1FEN1PDE4APDE4BPDE4C
SCHEMBL125349 0.72 FEN1 (0.49) LOXL3LOXL2ALDH1A1KDM4EFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353218-B2 Kit for multifunctional compounds forming crosslinked biomaterials ANGIOTECH PHARMACEUTICALS, INC. 2016-05-31 US disclosed
US-9326934-B2 Drug delivery from rapid gelling polymer composition ANGIOTECH INTERNATIONAL AG 2016-05-03 US disclosed
EP-2181704-B1 Drug delivery from rapid gelling polymer composition ANGIOTECH INT AG (CH) 2015-05-06 EP disclosed
US-20130289235-A1 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH PHARMACEUTICALS, INC. (CA) 2013-10-31 US disclosed
US-8486437-B2 Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2013-07-16 US disclosed
US-8481073-B2 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use ANGIODEVICE INTERNATIONAL GMBH (CH) 2013-07-09 US disclosed
US-8460708-B2 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use ANGIODEVICE INTERNATIONAL GMBH (CH) 2013-06-11 US disclosed
US-20130012683-A1 MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2013-01-10 US disclosed
US-8303973-B2 Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2012-11-06 US disclosed
US-20120252905-A1 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION ANGIOTECH INTERNATIONAL AG 2012-10-04 US disclosed
US-20050154374-A1 Implantable sensors and implantable pumps and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-07-14 US disclosed
US-20050152946-A1 Implantable sensors and implantable pumps and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-07-14 US disclosed
US-20050149157-A1 Electrical devices and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-07-07 US disclosed
US-20050149080-A1 Medical implants and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-07-07 US disclosed
US-20050149158-A1 Medical implants and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-07-07 US disclosed
US-20050143817-A1 Medical implants and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-06-30 US disclosed
US-20050142162-A1 Soft tissue implants and anti-scarring agents ANGIOTECH INTERNATIONAL AG (CH) 2005-06-30 US disclosed
US-20040260318-A1 Anastomotic connector devices ANGIOTECH INTERNATIONAL AG (CH) 2004-12-23 US disclosed
US-20040225077-A1 Drug delivery from rapid gelling polymer composition ANGIOTECH INTERNATIONAL AG (CH) 2004-11-11 US disclosed
US-20040219214-A1 Tissue reactive compounds and compositions and uses thereof ANGIOTECH INTERNATIONAL AG (CH) 2004-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040219214-A1 Tissue reactive compounds and compositions and uses thereof CD44, SELP, EPCAM LOXL3 271/4885LOXL2 330/4885ALDH1A1 1077/4885
US-20050152946-A1 Implantable sensors and implantable pumps and anti-scarring agents MMP1, CDKN1A, MKI67 LOXL3 753/4885LOXL2 502/4885ALDH1A1 1386/4885
US-20050142162-A1 Soft tissue implants and anti-scarring agents MMP1, COL2A1, FN1 LOXL3 67/4885LOXL2 78/4885ALDH1A1 1677/4885
US-20120252905-A1 DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION PGF, VCAM1, COL14A1 LOXL3 155/4885LOXL2 90/4885ALDH1A1 1262/4885
US-20050154374-A1 Implantable sensors and implantable pumps and anti-scarring agents MMP1, CDKN1A, MKI67 LOXL3 753/4885LOXL2 502/4885ALDH1A1 1386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.